In this podcast, The Bio Report’s Daniel Levine interviews BIO’s Dave Thomas on the recent release of a new BIO Industry Analysis report – Emerging Therapeutic Company Investment and Deal Trends – highlighting ten years (2005-2014) of biotechnology funding and deal making across five areas: venture capital, IPOs, follow-on public offerings, licensing, and acquisitions. The report also offers a first-time look at the degree of collaboration across the industry’s clinical pipeline.
Some of the key findings include:
- Venture Capital: A decade high in 2014 for US venture capital in Novel R&D lead programs. However, Series A investments went to fewer companies and with fewer dollars vs 2013. Additionally, some disease areas affecting large populations continue to see declines.
- IPOs: A decade high in 2014 for U.S. emerging company IPOs.
- Follow-On Offerings: A decade high in 2014 for U.S. emerging company follow-on offerings.
- Licensing: A decade high in 2014 for upfront payments in R&D-stage licensing deals.
- Acquisitions: R&D-stage acquisition volume is returning to levels not seen since 2008.
- Pipeline: Nearly 70% of the industry clinical pipeline is attributed to small emerging companies. A significant portion of the emerging company pipeline (43%) is partnered.
Furthermore, the report provides a more in-depth look at the major disease categories for drug R&D. This section showcases recent interest levels across the five investment and deal making activities with respect to each therapeutic area.
The podcast can be accessed here:
The free report – Emerging Therapeutic Company Investment and Deal Trends – can be accessed here. For more information on BIO Industry Analysis, please visit http://www.biotech-now.org/business-and-investments/inside-bio-ia.